ArticleJournal of thoracic disease2018
Durvalumab showed long and durable effects after chemoradiotherapy in stage III non-small cell lung cancer: results of the PACIFIC study.
Article in Journal of thoracic disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Real-world incidence and risk factors of pneumonitis in chemoradiation plus immune checkpoint inhibitors compared with chemoradiation alone in lung cancer: a retrospective cohort study.Translational lung cancer research · 2024Article
- Prognostic value of integrating circulating tumour cells and cell-free DNA in non-small cell lung cancer.Heliyon · 2022Article
- Durvalumab as Consolidation Therapy in Post-Multimodal Interventional Treatment for Patients with Advanced Solid Tumors: A Preliminary Study.Journal of oncology · 2022Article
- Current Progress and Future Perspectives of Immune Checkpoint Inhibitors in Biliary Tract Cancer.OncoTargets and therapy · 2021Review
- Management of Immune-Related Adverse Events in Patients With Non-Small Cell Lung Cancer.Frontiers in oncology · 2021Review
- Treatment of stage III non-small cell lung cancer in the era of immunotherapy: pathological complete response to neoadjuvant pembrolizumab and chemotherapy.Translational lung cancer research · 2020Review
- Efficacy and safety of recombinant human endostatin combined with radiotherapy or chemoradiotherapy in patients with locally advanced non-small cell lung cancer: a pooled analysis.Radiation oncology (London, England) · 2020Article
- Imperfect Predictors for Lung Cancer Immunotherapy-A Field for Further Research.Frontiers in oncology · 2020Review
- Survival score to characterize prognosis in inoperable stage III NSCLC after chemoradiotherapy.Translational lung cancer research · 2019Article
- Soluble immune checkpoint molecules: Serum markers for cancer diagnosis and prognosis.Cancer reports (Hoboken, N.J.) · 2019Review
- [Progress on PD-1/PD-L1 Checkpoint Inhibitors in Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2019Review
- Effect of Pretreatment Platelet Parameters on Survival in Limited Disease Small Cell Lung Cancer.Asian Pacific journal of cancer prevention : APJCP · 2019Article
- Treatment-duration is related to changes in peripheral lymphocyte counts during definitive radiotherapy for unresectable stage III NSCLC.Radiation oncology (London, England) · 2019Article
- Establishment and characterization of a patient-derived circulating lung tumor cell line in vitro and in vivo.Cancer cell international · 2019Article
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.